Welcome to CSNpharm! For Research Use Only!
FLT3
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN15695 | UNC2025 | 1429881-91-3 | UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 08 nM and 074 nM respectively |
| CSN19156 | UNC2025 hydrochloride | 2070015-17-5 | UNC2025 HCl is a potent and orally bioavailable MerFlt3 dual inhibitor with IC50 of 08074 nM for MerFlt3 |
| CSN12405 | Fedratinib | 936091-26-8 | TG 101348 is an inhibitor of JAK2 with an IC of 6 nM and also inhibits related kinases FLT3, RET, and JAK3 with less potent activity, having IC values of 25, 17 and 169 nM, respectively. |
| CSN13941 | TCS 359 | 301305-73-7 | TCS 359 a 2-acylaminothiophene-3-carboxamide is a potent inhibitor of FLT3 with IC50 of 42 nM |
| CSN12033 | Tandutinib | 387867-13-2 | Tandutinib is an antagonist of FLT3 with IC50 of 0.22 M and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis. |
| CSN24785 | TAK-659 | 1312691-33-0 | TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL)[1][2][3][4]. |
| CSN20533 | (Z)-SU5614 | 1055412-47-9 | SU-5614 is an inhibitor of FLT3 In BaF3 and AML cell lines expressing a constitutively activated FLT3 SU-5614 exhibits significant cell growth inhibition and cell cycle arrest |
| CSN13100 | Quizartinib | 950769-58-1 | Quizartinib is a second-generation FLT3 inhibitor for Flt3 ITDWT with IC50 of 11 nM42 nM being 10-fold selective for Flt3 than KIT PDGFR PDGFR RET and CSF-1R |
| CSN17212 | Pexidartinib | 1029044-16-3 | Pexidartinib is a small-molecule receptor tyrosine kinase RTK inhibitor of KIT CSF1R and FLT3 with IC50s of 20 10 and 160 nM in vitro respectively |
| CSN17304 | KW-2449 | 1000669-72-6 | KW-2449 is a multiple-targeted inhibitor mostly for Flt3 with IC50 of 66 nM modestly potent to FGFR1 Bcr-Abl and Aurora A and showing little effect on PDGFR IGF-1R EGFR |
| CSN13926 | Gilteritinib | 1254053-43-4 | Gilteritinib is a potent FLT3AXL inhibitor with IC50 of 029 nM 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations |
| CSN21227 | Gilteritinib hemifumarate | 1254053-84-3 | Gilteritinib hemifumarate is an inhibitor of FLT3 and AXL with IC50 of 0.29 nM and 0.73 nM, respectively. |
| CSN13783 | G-749 | 1457983-28-6 | G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 04063575 nM for Wt Flt3D835YMV4-11Molm-14 respectively |
| CSN16867 | FLT3-IN-2 | 923562-23-6 | FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 M |
| CSN21240 | (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide succinate(1:x) | 1702864-11-6 | FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A |
| CSN21235 | FF-10101 | 1472797-69-5 | FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A |
| CSN16265 | SKLB4771 | 1370256-78-2 | FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM |
| CSN27527 | Fedratinib hydrochloride hydrate | 1374744-69-0 | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
| CSN32928 | Famitinib malate | 1256377-67-9 | Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment. |
| CSN20591 | Famitinib | 1044040-56-3 | Famitinib a structural analogue of sunitinib is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma gastrointestinal stromal tumours pancreatic cancer and nasopharyngeal carcinoma |
| CSN18598 | ENMD-2076 | 934353-76-1 | ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 186 nM 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR |
| CSN24802 | BPR1K871 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
| CSN16269 | CTX-0294885 | 1439934-41-4 | CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen. |
| CSN18820 | Crotonoside | 1818-71-9 | Crotonoside is a naturally occurring active isomer of guanosine found in the seeds of Croton tiglium, which could reduce the blood pressure in rabbits and cats. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML. |
| CSN27200 | CCT241736 | 1402709-93-6 | CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively. |
| CSN15710 | Cabozantinib | 849217-68-1 | Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-134, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM11.3 nM6 nM, 14.3 nM and 7 nM, respectively. |
| CSN16257 | BPR1J-097 | 1327167-19-0 | BPR1J-097 is a small molecule FLT-3 inhibitor IC50117 nM with promising in vivo anti-tumour activities inhibiting FLT-3 D835Y with an IC50 of 3 nM |
| CSN19120 | BBT594 | 882405-89-2 | BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment. |
| CSN25237 | ATH686 | 853299-52-2 | ATH686 is the second-generation FLT3 inhibitor. |
| CSN18365 | AST 487 | 630124-46-8 | AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM. |
| CSN22654 | 5'-Fluoroindirubinoxime | 861214-33-7 | 5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) with IC50 of 15 nM. |
| CSN64929 | ENMD-2076 Tartrate | 1453868-32-0 | |
| CSN67441 | OTS447 | 1356943-67-3 | |
| CSN51530 | 9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine | 1350544-93-2 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
